Table 1

Baseline characteristics according to first pass effect in the ASTER trial

Characteristics FPE (n=97) Non-FPE (n=239)P valueRR (95% CI)
Demographics
 Age, years, mean (SD)70.5 (14.0)69.0 (14.9)0.131.06 (0.98 to 1.14)*
 Men44/97 (45.4)130/239 (54.4)0.180.76 (0.50 to 0.15)
Medical history
 Hypertension53/95 (55.8)145/235 (61.7)0.120.84 (0.66 to 1.05)
 Diabetes19/96 (19.8)49/234 (20.9)0.530.94 (0.77 to 1.15)
 Hypercholesterolemia34/96 (35.4)86/232 (37.1)0.680.95 (0.75 to 1.20)
 Current smoking16/76 (21.1)41/206 (19.9)0.771.07 (0.68 to 1.67)
 Coronary artery disease14/95 (14.7)45/232 (19.4)0.100.77 (0.56 to 1.06)
 Previous stroke or TIA20/96 (20.8)39/236 (16.5)0.191.23 (0.90 to 1.70)
 Previous antithrombotic medications43/93 (46.2)118/237 (49.8)0.280.89 (0.72 to 1.10)
  Antiplatelet28/93 (30.1)76/237 (32.1)0.500.93 (0.75 to 1.15)
  Anticoagulant15/93 (16.1)50/237 (21.1)0.0830.75 (0.53 to 1.04)
Current stroke event
 Systolic blood pressure, mm Hg, mean (SD)†148 (25)146 (26)0.261.03 (0.98 to 1.08)*
 NIHSS score, mean (SD)‡15.8 (6.5)16.4 (6.0)0.270.94 (0.84 to 1.05)§
 Pre-stroke mRS score ≥124/96 (25.0)33/239 (13.8)<0.0011.64 (1.23 to 2.17)
 ASPECTS, median (IQR)¶8 (6 to 9)7 (5 to 9)0.0141.08 (1.01 to 1.15)**
 Site of occlusion
  M1-MCA61/97 (62.9)134/239 (56.1)0.311.00 (reference)
  M2-MCA23/97 (23.7)53/239 (22.2)1.00 (0.61 to 1.62)
  Intracranial ICA or tandem13/97 (13.4)52/239 (21.8)0.63 (0.34 to 1.16)
 Favorable collaterals23/81 (28.4)43/184 (23.4)0.401.20 (0.78 to 1.84)
 Clot length, mm, median (IQR)††11 (8 to 16)13 (9 to 20)0.0980.97 (0.94 to 1.01)**
 Clot burden, median (IQR)‡‡6 (4 to 8)7 (5 to 8)0.180.97 (0.93 to 1.02)**
 Suspected stroke cause
  Large artery atherosclerosis10/97 (10.3)18/239 (7.5)0.151.00 (reference)
  Cardioembolic33/97 (34.0)109/239 (45.6)0.66 (0.41 to 1.05)
  Other or unknown54/97 (55.7)112/239 (46.9)0.91 (0.65 to 1.27)
 Intravenous rtPA61/97 (62.9)155/239 (64.9)0.510.94 (0.78 to 1.13)
Endovascular treatment
 General anesthesia7/97 (7.2)38/239 (15.9)0.0770.50 (0.23 to 1.08)
 Onset to groin puncture time, min, median (IQR)‡230 (179 to 283)230 (184 to 279)0.341.02 (0.97 to 1.07)§ §
  Onset to imaging108 (80 to 149)114 (84 to 150)0.341.02 (0.97 to 1.07)§ §
  Imaging to groin puncture112 (69 to 154)110 (62 to 150)0.931.00 (0.90 to 1.12)§ §
  • Values expressed as no/total no (%) unless otherwise indicated.

  • *OR calculated per 10 unit increase.

  • †Nine missing values.

  • ‡Three missing values.

  • §OR calculated per 30 unit increase.

  • ¶Four missing values.

  • **OR calculated per 1 unit increase.

  • ††Seventy-six6 missing values.

  • ‡ ‡One hundred and five missing values.

  • § §OR calculated per 30 unit increase.

  • ASPECTS, Alberta Stroke Programme Early CT score; FPE, first pass effect; ICA, internal carotid artery; MCA, middle cerebral artery; mRS, modified Rankin Scale, NIHSS, National Institutes of Health Stroke Scale; rtPA, recombinant tissue plasminogen activator; TIA, transient ischemic attack.